THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES

Authors :: M. V. Shestakova
S. A. Boytsov
O. M. Drapkina
T. Yu. Demidova
H. Drexel
M. B. Antsiferov
N. A. Petunina
N. A. Chernikova
V. Yu. Kalashnikov
T. P. Bardymova
V. K. Protasov
A. Yu. Babenko
L. A. Ruyatkina
V. V. Klimontov
V. V. Salukhov
V. V. Fadeev
Yu. A. Karpov
Source :: Рациональная фармакотерапия в кардиологии, Vol 12, Iss 2, Pp 186-190 (2016)
Publication Year :: 2016
Publisher :: Столичная издательская компания, 2016.
Abstract: The interdisciplinary interim experts’ council on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of propositions and recommendations on further empagliflozin’s cardiovascular effects investigation and its clinical application in patients with type 2 diabetes at high cardiovascular risk.